NEW YORK, March 4 - Genome Therapeutics reported today a fall-off in revenues for the fourth quarter ended December 31, 2002, along with lower R&D spending and a slightly increased net loss.

 

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have an account?
Login Now.

Researchers hope to tease out the signature effects that different carcinogens leave on the genome to determine their contributions to disease, Mosaic reports.

An Imperial College London-led team reports that it was able to use a gene drive to control a population of lab mosquitos.

The Wall Street Journal looks into the cost of new gene therapies.

In PNAS this week: genomic effects of silver fox domestication, limited effect of mitochondrial mutations on aging in fruit flies, and more.